Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (MDGL) Revenue
Annual & quarterly revenue history · segment & region breakdown
MDGL · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsMadrigal Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $1.13B, an increase of 432.05% year-over-year from $0.96B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.96B | +$0.78B | +432.05% |
| 2024-12-31 | $0.18B | +$0.18B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare MDGL revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Madrigal Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Madrigal Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Madrigal Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MDGL revenue · 4 questionsMDGL's trailing twelve-month (TTM) revenue is $1.13B. That is an increase of 432.05% year-over-year from $0.96B in FY2025.
▸ Source: FMP · Madrigal Pharmaceuticals, Inc. SEC filings · GAAP · Madrigal Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026